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A B S T R A C T
Background: Neurotrophins such as brain-derived neurotrophic factor (BDNF), inflammation and
oxidative damage may contribute to the pathophysiology of bipolar disorder (BD) in terms of illness
activity. To date, there is a lack of studies linking the cognitive impairment observed in BD with these
neurobiological mechanisms. This study aimed to investigate the role of these neurobiological factors in
clinical and cognitive outcomes in a sample of bipolar individuals.
Methods: We measured serum BDNF, cytokines and oxidative stress markers in a sample of 133
individuals: 52 euthymic bipolar patients, 32 manic patients and 49 healthy controls. They were all
assessed with a comprehensive cognitive battery. Sociodemographic and clinical data were collected.
Multiple linear regression models were built to study associations of neurotrophins and inflammatory
and oxidative measures with cognitive functioning.
Results: BDNF levels were decreased in euthymic (p = 0.039) and manic (p < 0.001) individuals. Conversely,
inflammatory (interleukin 6 (IL-6)) (p = 0.019) and oxidative stress (p = 0.003) measures were increased in
bipolar individuals compared to controls. BDNF levels were associated with executive functioning (β = 0.01,
p = 0.02) and verbal memory (β = 0.013, p = 0.005), together with other demographic variables. In particular,
verbal memory was also associated with obesity (β=-0.04, p = 0.005). Neither inflammatory markers,
oxidative stress markers nor other relevant clinical variables showed any association with cognitive
outcome.
Conclusions: Of all the peripheral neurobiological factors analysed, BDNF was the only one significantly
associated with cognitive dysfunction in bipolar disorder individuals. This study emphasizes the role of
BDNF not only across mood phases but also in cognitive functioning.
© 2019 Elsevier Masson SAS. All rights reserved.
Contents lists available at ScienceDirect
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Bipolar disorder (BD) is a recurrent mood disorder affecting 1–3%
of the world population [1]. It has a long-term outcome with
incomplete recovery between episodes, cognitive impairment, and* Corresponding autor at: Hospital Sant Joan de Déu Terres de Lleida, La Canadiense
** Corresponding author at: Department of Psychiatry, Hospital Santa Creu i Sant Pau
Catalonia, Spain.
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0924-9338/© 2019 Elsevier Masson SAS. All rights reserved.functional decline [1–6]. Its chronic course is associated with high
rates of morbidity and mortality, making bipolar disorder one of the
main causes of disability among young and working-age people [7].
Cognitive dysfunction is the key feature of functional impairment
throughout periods of mania, depression and euthymia in BD [8]. Avenue, 26, 25001, Lleida, Catalonia, Spain.
, Autonomous University of Barcelona, St. Antoni M. Claret, 167, 08025, Barcelona,
ortella).
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remain unknown in psychiatric disorders [9]. Cognition is affected
by a range of medical issues and neurochemical mechanisms [10].
There is evidence that endocrine (such as obesity) and cardiovas-
cular issues which are more common in BD than in general
population [11,12], may be negatively associated with cognitive
progression [13,14].
Cognition is better understood in terms of complex networks
operating over multiple temporal scales and incorporating various
dimensions: from cellular cascades to cerebral circuits and,
ultimately, society [9]. Moreover, a diverse palette of neuro-
modulators including acetylcholine, cytokines and neurotrophic
proteins such as brain-derived neurotrophic factor (BDNF)
influence cognitive performance [9]. In the same line, there are
some neurobiological factors such as BDNF, immune-inflammatory
and oxidative stress markers that have been consistently reported
to be associated with brain structure and function and to be
relevant to physiological and pathological neurodevelopment
[15,16]. Associations between alterations in these systems have
been reliably described in children and adults, across different
mental disorders [17,18]. In particular, compelling evidence about
these neurobiological factors in bipolar disorder has been found
[19–21]. Indeed, several pathophysiological mechanisms have
been proposed and investigated, to understand the interaction
between these neurobiological factors and mood symptomatology
in BD [16,22,23]. However, significantly less investigation has been
conducted to elucidate the effect of inflammation, oxidative stress
and neuroplasticity on cognition in BD [24,25].
The main aim of the current study was to investigate the
association of cognitive performance with neuroprotective and
neurodegenerative mechanisms (neurotrophins, and inflamma-
tion and oxidative stress markers) in patients with BD. We
hypothesized that (1) bipolar individuals (euthymic and manic)
would display a different pattern of BDNF, inflammatory-cytokine
and oxidative stress markers as compared to healthy controls; and
(2) cognitive performance would be associated with these
neurobiological factors regardless of mood state.
2. Methods
2.1. Participants
A total of 133 individuals were enrolled in the study: 49 healthy
controls, 52 euthymic bipolar and 32 manic bipolar individuals. All
of them were evaluated by clinical interview with a psychiatrist,
and underwent neuropsychological and biochemical tests.
Euthymic bipolar patients were recruited from the Outpatient
Lithium Clinic at Hospital Universitari Santa Maria, Lleida, from
2003 until 2011. All of them met Diagnostic and Statistical Manual
of Mental Disorders, fourth edition, text revision (DSM-IV-TR)
criteria for BD, as was determined by a Psychiatrist using the
Structured Clinical Interview for Axis I Disorders [26]. They were
aged between 18 and 65 years old. Euthymia state was determined
when bipolar individuals obtained a total 17-item Hamilton Rating
Scale for Depression (HAMD) [27] score below 8 and a total Young
Mania Rating Scale (YMRS) [28] score below 6 for at least 3 months
prior to the assessment [29]. Significant non-psychiatric illness,
substance abuse or dependence or electroconvulsive therapy
during the preceding year, were the exclusion criteria.
Manic bipolar patients were recruited from the Inpatient
Psychiatric Unit, at Hospital Universitari Santa Maria, Lleida,
during a manic phase, from 2012 until 2014. Inclusion and
exclusion criteria were the same as for euthymic patients, except
for the criteria of clinical stability: manic patients were included if
they had a total score of 14 or above in the YMRS [30]. Blood
extraction was performed at the beginning of the hospitalization inthe acute phase of the disorder. Cognitive assessment was
performed just prior to discharge when major manic symptoms
were partially remitted, in order to guarantee collaboration of
manic patients, without biasing cognitive performance, even
though it meant gathering information at two separate points in
time.
Forty-nine healthy controls were enrolled with advertise-
ments and from non-medical hospital staff. Controls had no
current or past psychiatric history, as determined by the
Structured Clinical Interview for DMS-IV Axis I Disorders [26].
Additionally, healthy subjects were excluded if there was a family
history of any Axis I disorder in a first-degree relative. Healthy
subjects underwent the same exclusion criteria as the patients,
and were assessed at the same full clinical and demographics
interview by a trained psychiatrist. The Local Ethics Committee
approved the study and written informed consent was obtained
from all participants.
2.2. Demographic, clinical and pharmacological data
Demographic variables included age, gender, years of education
and current work status. Body mass index (BMI) was also
calculated for each participant. The established criteria for BMI
were: normal weight, BMI of 18.5–24.9 kg/m2; overweight, BMI of
25.0–29.9 kg/m2; and obese, BMI > 30 kg/m2 (National Heart LaBI
NI of D and D and KD [31]. Psychiatric variables were obtained from
the sample of bipolar patients, including: age at onset of illness,
number of prior manic episodes and hospitalizations, period of
stabilization (years), history of psychotic symptoms, seasonal
pattern, suicide attempts and bipolar subtype (I or II) during the
psychiatric interview. Other physical and medical issues (e.g.
cardiovascular, neurological, gastrointestinal, haematological, re-
nal, hepatic, respiratory or endocrine illnesses) and concurrent
psychiatric and non-psychiatric medications were recorded in the
same interview. Biochemical tests were performed in all patients,
including thyroid function, lipid profile, serum lithium levels and
urine drug testing.
2.3. Neuropsychological assessment
To characterize the cognitive functioning, a selected battery
that included neuropsychological tasks covering the most im-
paired cognitive domains in BD, i.e. executive and memory
functioning [3,29,32] was administered to all participants. The
estimated mean intelligence quotient (IQ) of the subjects was
obtained from the weighted scores of the Vocabulary and Block
Design subtests of the Wechsler Adult Intelligence Scale (WAIS-III)
[33], on the basis that these two scores are highly correlated with
total IQ.
The instruments administered were:
i Vocabulary, Block Design and Digits Subtests from WAIS-III
[33];
ii Wisconsin Card Sorting Test (WCST) [34], to assess executive
function and perseverative behaviour;
iii Stroop Color and Word Test [35], to evaluate selective attention
and inhibition capacity;
iv FAS verbal fluency task of the Controlled oral Word Association
Test/Categories [36], to assess executive function;
v Trail making Test (TMT), to evaluate processing speed parts A
(TMT-A) and cognitive flexibility parts B (TMT-B) [37];
vi Conners’ continuous Performance Test II (CPT-II) [38], to
evaluate sustained attention, processing speed, and persever-
ative behavior;
vii The California Verbal Learning Test (CVLT) [39], to evaluate
verbal learning, recall, and recognition;
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2.4. Biochemical measures
For each participant (patients and healthy controls), blood
samples were collected between 8:00 and 9:00 to avoid variations
due to the circadian rhythm. Ten millilitres of blood were
withdrawn from all participants by venipuncture into a free-
anticoagulant vacuum tube. Serum was separated within 2 h by
centrifugation at 3500 g during 15 min at room temperature. All
samples were stored at 80 C until assayed in the IRBLleida Biobanc
(B.0000682) and PLATAFORMA BIOBANCOS PT13/0010/0014.
Afterwards, neurobiological factors were determined and all
samples were assayed in duplicates. The neurobiological factors
related to neurotrophins, inflammation and oxidative stress were
examined as follows:
 Brain-derived neurotrophic factor (BDNF) serum levels were
measured with sandwich-ELISA, using a commercial kit
according to the manufacturer’s instructions (Chemicon, Teme-
cula, CA, USA), as previously described [41]. All samples were
assayed in duplicates. The results were expressed as ng/ml.
Intra- and inter-assay coefficients of variation were <12%.
 Serum pro-inflammatory cytokines, such as interleukin 6 (IL-6)
and tumour necrosis α (TNF-α) and an anti-inflammatory
cytokine, interleukin 10 (IL-10) were measured according to
the procedures supplied by the manufacturer using highly
sensitive sandwich-ELISA kits for TNF-α, IL-6 and IL-10
(Quantikine, R&D Systems, Minneapolis, Minn., USA). All
samples were assayed in duplicates. The results were expressed
as ng/ml. Intra- and inter-assay coefficients of variation were
<10%.
 Oxidative damage was measured by the levels of lipid peroxida-
tion using the thiobarbituric acid reactive substances (TBARS)
method described by Wills [42]. All samples were assayed in
duplicates and the results were expressed as nmol/mL.
2.5. Statistical procedure
Data analyses were carried out with the statistical package SPSS
for Windows, version 22.0 (SPSS Inc., USA) and R statistical
software (version 3.2.2) [43]. Demographics, clinical, and phar-
macological characteristics of groups were compared with analysis
of variance (ANOVAs) for continuous variables and Chi-square (or
Fisher’s exact test) for categorical variables as descriptive statistics
analyses. All variables were assessed for normality and those
variables that were not normally distributed were log-trans-
formed. To counteract the problem of multiple comparisons,
Bonferroni correction was performed on variables that displayed
statistical differences between the three groups in the ANOVAs.
Performance on neuropsychological tasks was compared among
three groups using a multivariate analysis of variance (MANOVA),
and post-hoc analyses were then performed to establish pairwise
differences. Neurobiological variables were also analysed with
MANOVA, and post-hoc analyses. Parametric and non-parametric
correlations were carried out to explore associations between
clinical, demographical and neurobiological variables to be
included in further analyses. Multiple linear regression models
were built to study the association between different variables
(demographics and neurobiological factors) and cognitive func-
tioning. For this purpose, neuropsychological tasks were z-
transformed and grouped by cognitive domains (i.e., executive
function, processing speed, inhibition, attention, and verbal andvisual memories) based on our previous work [44]. A composite
score was created for each cognitive domain, which included all
the tests encompassed within each domain (see Table 2). The
composite score was calculated as an arithmetic mean and it was
used to avoid redundant information of separate tests. On
measures of reaction time (low scores indicating good perfor-
mance), z-scores were reversed before forming the composite
score. Each cognitive composite score was then used as a
dependent variable in the regression models. Multicollinearity
was checked for each model using tolerance and variance inflation
factor (VIF) criteria. Significant or relevant demographic variables,
such as current age, premorbid IQ, BMI and neurobiological
variables were included as predictive factors. The obtained results
will be explained using standardized coefficient (β) and p values.
Firstly, in order to elucidate the role of clinical and neurobio-
logical factors on cognitive functioning, Pearson’s correlations
were performed between these variables. Further regression
models were then carried out in the sample of patients (euthymic
and manic individuals) including the independent factors men-
tioned above together with duration of illness, number of manic
and depressive episodes and number of hospitalizations.
3. Results
3.1. Demographic and clinical characteristics of the sample
Demographics, clinical features and neurobiological factors
levels of the 133 participants are depicted in Table 1. Euthymic
bipolar patients and healthy controls were comparable in age and
gender. There were statistical differences between groups in terms
of years of education, IQ, BMI, HAMD and YMRS.
With respect to pharmacological variables, most of euthymic
bipolar patients (81%) were on lithium treatment (15 patients were
on lithium monotherapy and 27 on combination treatment -plus
antidepressant or antipsychotic-). Off the manic bipolar patients
group, half of them (16 individuals) were on lithium combination
treatment and the other half (16 individuals) with another mood
stabilizer plus antipsychotic (i.e., valproate; see Table 1).
In terms of medical issues, there was a history of cardiovascular
and endocrine issues in all groups without statistical differences
(χ2 = 11.8, df = 16, p = 0.76). Particularly, they had high blood
pressure (9 healthy controls, 4 euthymic and 2 manic bipolar
individuals), history of diabetes mellitus type 2 (4 healthy controls,
3 euthymic and 1 manic bipolar individuals), and subclinical (4
euthymic bipolar individuals) and clinical (2 manic) hypothyroid-
ism. Regarding body mass index (BMI), euthymic bipolar
individuals were more overweight than manic individuals and
healthy controls (F = 4.8; p = 0.01).
3.2. Neuropsychological performance
All neuropsychological variables included in each cognitive
domain and univariate effects are listed in Table 2. As expected, in
the post-hoc analyses, euthymic and manic individuals performed
worse compared to healthy control group (p < 0.0001) in executive
functioning, inhibition, processing speed, verbal and visual
memory (see Fig. 1). The only domain that displayed statistical
differences between euthymic and manic groups was verbal
memory (p < 0.0001), in which euthymic patients showed better
performance than manic patients, but worse than healthy controls.
3.3. Descriptive analyses of neurobiological factors and associations
with demographic, clinical and pharmacological variables
BDNF levels in both groups of bipolar patients (euthymic and
manic individuals; p = 0.039 and p < 0.0001 respectively) were
Table 1







F or χ2/p Bonferroni post-Hoc
Age, y 48.3 (12.1) 47.52 (11.9) 41.25 (12.9) 3.6/0.029 HC>Ma
Gender, (number of males, %) 21 (42.9) 26 (50) 18 (56.3) 1.43/NS
Mean estimated premorbid IQ 115.3 (9.9) 102.6 (11.6) 97.8 (11.6) 28.6/<0.0001 HC>Eu; HC>Ma
Current work status, N (%)
Active 40 (81.6) 21 (40.4) 13 (40.6) 28/*
Inactive 2 (4.1) 7 (13.5) 10 (31.3)
Retired/Disabled 7 (14.3) 24 (46.2) 9 (28.1)
Positive family history of mental illness, N (%) 18 (36.7) 39 (75) 15 (46.9) 15.8/*
Education, y 12.7 (2.9) 10.3 (2.7) 11.75 (3.4) 7.9/0.001 HC>Eu
GAF score NA 73 (9.5) 31.41 (7.1) 545.8/*
BMI, kg/m2 26.5 (5) 29 (4.6) 26.5 (3.8) 0.010 Eu>HC; Eu>Ma
Clinical Variables
YMRS score 0.6 (1.1) 1.4 (1.7) 31.3 (5.9) 1118.2/* Ma>Eu; Ma>HC
HAM-D score 0.9 (1.4) 2.4 (2.3) 8.3 (3.7) 100/* Ma>Eu>HC;
Age of onset, y NA 24.5 (10.3) 29.3 (10.7) 4.2/0.043 Ma>HC
No. of hospitalizations NA 2.7 (2.7) 3 (2.6) 0.3/NS
Duration of illness, y NA 22.9 (12.4) 11.9 (11.2) 16.8/*
Total no. of manic episodes NA 2.6 (2.7) 2.9 (3.7) 0.2/NS
Years of stabilization NA 6 (5.9) 3 (3.4) 6.8/0.011
Lifetime history of psychotic symptoms, N (%) NA 41 (78.8) 27 (84.4) 0.39/NS
Lifetime history of seasonal pattern, N (%) NA 29 (55.8) 18 (56.3) 0.002/NS
Personal history of suicide attempts, N (%) NA 20 (38.5) 6 (18.8) 3.6/0.06
Diagnosis, N (%)
Bipolar I disorder NA 34 (65.4) 31 (96.9) 11.1/0.001
Bipolar II disorder NA 18 (34.6) 1 (3.1)
Type of current medication, N (%)
Lithium monotherapy NA 15 (28.8) 0 18.8/*
Lithium + combination NA 27 (51.9) 16 (50)
Valproate + combinarion NA 8 (15.4) 16 (50)
None NA 2 (3.8) 0
Lithium
Years of treatment, y NA 9.2 (6.7) 1.2 (1.6) 21.6/*
Serum lithium levels, mml/dL NA 0.7 (0.2) 0.65 (0.1) 0.7/NS
Lithium dosage, mg/day NA 1128.6 (278.7) 1062.5 (215.6) 0.7/NS
Biomarkers
BDNF, ng/ml 45.86 (13.6) 40 (9.9) 35.05 (10.6) 8.6/* HC>Eu; HC>Ma
logIL-6 0.86 (0.5) 1.09 (0.6) 1.23 (0.7) 4.1/0.018 Ma>HC
logIL-10 2.24 (0.4) 1.18 (1.4) 1.18 (1.4) 12.5/* Ma>HC; Eu>HC
logTNF 0.51 (2.4) 0.04 (2.8) 0.71 (2.8) 2/0.14
logTBARS 2.51 (0.6) 3.08 (1) 2.79 (0.9) 5.6/0.005 Eu>HC
Values represent mean (SD) unless otherwise specified
Statistics of between-subject effects from the multivariate analyses of variance. Abbreviations: GAF = Global Assessment of Functioning, YMRS = Young Mania Rating Scale,
HAM-D = Hamilton Rating Scale for Depression, NA = Not applicable, NS = Not significant. HC=Healthy Controls, Eu=Euthymic Patients, Ma=Manic patients. *=<0.0001.
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pro-inflammatory cytokine interleukin 6 (IL-6) levels were signifi-
cantly higher in the group of manic patients compared to healthy
controls (p = 0.019), and the anti-inflammatory interleukin 10 (IL-10)
levels were higher in both groups of patients compared to healthy
controls (both comparisons with statistical significance; p < 0.0001).
Levels of TBARS were higher in euthymic bipolar group compared to
healthycontrols(p = 0.003); but therewere not statisticaldifferences
between manic patients group and the other groups.
Correlations between neurobiological factors and demographic
variables showed that there was an association between IL-6 and
BMI (r = 0.515; p < 0.0001) and with current age (r = 0.313;
p < 0.0001) in all participants. Premorbid IQ displayed a significant
relationship with IL-10 (r=0.268; p = 0.002) and with levels of
oxidative damage (TBARS; r=0.247; p = 0.005).
BDNF showed a negative correlation with HDRS (r=0.251,
p = 0.004) and YMRS (r=0.284, p = 0.001) in all participants.
Conversely, as it was expected, IL-6 displayed a positive association
with the same scales (HDRS: r = 0.176, p = 0.045; and YMRS:
r = 0.192, p = 0.029). IL-10 did not show any association with these
scales. When analysing patients alone (euthymic and manic),
correlations between clinical variables and neurobiological factors
showed that only IL-6 was associated with duration of illness
(r = 0.245; p = 0.025).Regarding pharmacological treatment, most bipolar euthymic
patients and half of the manic patients were on lithium treatment.
There was not any association between lithium and neurobiologi-
cal factors levels, with the exceptions of IL-6, which correlated
positively with lithium levels (r = 0.33; p = 0.011); and T-BARS,
where patients who were on lithium combination treatment
displayed higher levels (F = 4.7; p = 0.035) compared to patients
who were on lithium monotherapy.
Bipolar type I and type II euthymic individuals did not display
any statistical differences in neurobiological factors levels (data
not shown).
3.4. Association of neurobiological factors, demographics and BMI
with cognitive functioning
Six regression models were performed, one for each neuropsy-
chological domain in order to explore the association of
neurobiological factors and other demographic variables with
cognitive functioning (see Table 3). Only the models of executive
functioning and verbal memory were significant, with a R2 = 0.56
and 0.58, respectively. In particular, BDNF (β = 0.01, p = 0.02) was
the only neurobiological factor that explained executive function-
ing together with other variables: being manic (β=0.4, p = 0.012),
current age (β=0.023, p < 0.0001) and premorbid IQ (β = 0.03,
Table 2
Neuropsychological Test Results: Comparison of Euthymic Bipolar and Manic Patients and Healthy Controls.






F/p Bonferroni Post Hoc
Executive Functioning Domain <0.0001 HC>Eu; HC>Ma
TMT part B 62.1 (26) 117 (72.2) 117.9 (64.3) 13/<0.0001 HC>Eu; HC>Ma
FAS 43.47 (9.2) 34.25 (11.6) 37.16 (11.9) 8.8/<0.0001 HC>Eu; HC>Ma
WAIS-III digit span backward 6.51 (1.8) 5.06 (2) 4.31 (1.6) 14.8/<0.0001 HC>Eu; HC>Ma
Number of categories WCST 4.16 (2) 3.13 (2) 1.94 (1.5) 12.4/<0.0001 HC>Eu >Ma; HC>Ma
Inhibition Domain <0.0001 HC>Eu; HC>Ma
Stroop inhibition 45.87 (9.6) 34.94 (11.9) 30.47 (11.4) 38.5/<0.0001 HC>Eu; HC>Ma
No. of perseverative errors WCST 10.6 (9.5) 16.81 (12.7) 10.87 (6.5) 5.4/0.006 HC>Eu; Ma>Eu
No. of perseverative errors CPT 0.24 (0.6) 2.42 (4.3) 3.35 (3.6) 9.1/<0.0001 HC>Eu; HC>Ma
Attention Domain 0.002 HC>Eu
Stroop interference 4.92 (7.7) 2.63 (10.7) 0.4 (8.9) 3.1/0.05 HC>Ma
WAIS-III digit span forward 8.76 (1.9) 8.06 (2.1) 8.34 (1.6) 1.6/0.21 NS
CPT-II detectability 1.02 (0.4) 0.72 (0.4) 0.7 (0.5) 7.3/0.001 HC>Eu; HC>Ma
Processing Speed Domain <0.0001 HC>Eu; HC>Ma
TMT part A 32.4 (12.5) 54 (30.4) 50.19 (19.9) 11.5/<0.0001 HC>Eu; HC>Ma
CPT-II hit reaction time 428.43 (63.3) 479.18 (98.4) 501.65 (103.2) 6.9/0.001 HC>Eu; HC>Ma
Verbal Memory <0.0001 HC>Eu >Ma; HC>Ma
CVLT first trial 7.07 (2.1) 5.9 (2) 4.94 (1.6) 11.4/<0.0001 HC>Eu; HC>Ma
CVLT total words 58.93 (7.5) 48.13 (12.1) 40.34 (10.6) 31.9/<0.0001 HC>Eu >Ma; HC>Ma
CVLT immediate recall 13.93 (2) 10.12 (3.7) 7.06 (3.5) 45.7/<0.0001 HC>Eu >Ma; HC>Ma
CVLT delayed recall 14.56 (1.6) 11.19 (3.1) 7.28 (3.6) 51.3/<0.0001 HC>Eu >Ma; HC>Ma
CVLT recognition 15.82 (0.4) 14.62 (1.7) 14.03 (2.6) 11.2/<0.0001 HC>Eu; HC>Ma
Visual Memory <0.0001 HC>Eu; HC>Ma
RCFT immediate recall 25.22 (4.9) 18.2 (6.5) 16 (7.4) 23.8/<0.0001 HC>Eu; HC>Ma
RCFT delayed recall 25.26 (5.5) 19.26 (7.3) 15.22 (7.9) 20.7/<0.0001 HC>Eu >Ma; HC>Ma
aValues shown as mean (SD).
Statistics of between-subject effects from the multivariate analyses of variance.
Abbreviations: CVLT = California Verbal Learning Test, TMT = Trail Making Test, RCFT=Rey Complex Figure Test, HC=Healthy Controls, Eu=Euthymic Patients, Ma=Manic
patients.
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p < 0.0001) (see Fig. 2). Again BDNF (β = 0.013, p = 0.005) together
with BMI (β=-0.4, p = 0.005) and other variables [being euthymic
(β=0.345, p = 0.019), being manic (β=1.07, p < 0.0001), current age
(β=-0.015, p = 0.002) and premorbid IQ (β = 0.018, p < 0.0001)]
predicted worse performance in verbal memory, and explained a
58% of variance (F = 17.2; df = 9.115; p < 0.0001) (see Fig. 2). The rest
of neurobiological factors did not predict any other cognitive
domain, although the models were significant.Fig. 1. Neuropsychological performance adjusted by age, pre3.5. Association of neurobiological factors and clinical variables with
cognitive functioning in Bipolar Patients
Again six regression models were performed only analysing
euthymic and manic bipolar individuals (see Table 4). Current age and
premorbid IQ were predictor factors in all models (p < 0.05). Being a
manic bipolar individual was associated with worse performance in
executive functioning (β=0.33, p = 0.029), verbal memory (β=0.864,
p < 0.0001) and visual memory (β=0.459, p = 0.039).morbid IQ and years of education from all participants.
Table 3
Multiple regression models of the association between neurobiological factors and cognition in bipolar disorder individuals (euthymic an manic) and healthy controls. The
values correspond to all factors included in the models. Please note that only Executive Functioning and Verbal Memory models were the only that neurobiological factors
were significant.
Cognitive Domain Predictor β Standard error β Standardized β p
Executive Functioning Euthymic 0.221 0.130 0.145 0.092
Maniac 0.403 0.158 0.232 0.012
Current age 0.023 0.004 0.395 <0.0001
Premorbid IQ 0.030 0.004 0.532 <0.0001
BDNF 0.010 0.004 0.155 0.020
logIL6 0.022 0.098 0.017 0.826
logTNF 0.001 0.018 0.005 0.939
logTBARS 0.029 0.057 0.034 0.610
BMI 0.014 0.012 0.087 0.259
Inhibition Euthymic 0.389 0.154 0.251 0.013
Maniac 0.422 0.188 0.238 0.026
Current age 0.023 0.005 0.378 0.000
Premorbid IQ 0.022 0.005 0.387 0.000
BDNF 0.004 0.005 0.059 0.445
logIL6 0.018 0.117 0.014 0.878
logTNF 0.023 0.021 0.081 0.271
logTBARS 0.083 0.067 0.096 0.215
BMI 0.010 0.014 0.063 0.486
Attention Euthymic 0.185 0.136 0.153 0.177
Maniac 0.009 0.166 0.007 0.956
Current age 0.011 0.004 0.241 0.011
Premorbid IQ 0.011 0.005 0.248 0.017
BDNF 0.007 0.004 0.152 0.085
logIL6 0.024 0.103 0.024 0.817
logTNF 0.020 0.019 0.092 0.272
logTBARS 0.089 0.059 0.132 0.135
BMI 0.004 0.013 0.033 0.745
Processing speed Euthymic 0.554 0.162 0.324 0.001
Maniac 0.781 0.197 0.400 <0.0001
Current age 0.036 0.005 0.542 <0.0001
Premorbid IQ 0.016 0.005 0.244 0.005
BDNF 0.003 0.005 0.039 0.591
logIL6 0.038 0.123 0.026 0.759
logTNF 0.001 0.022 0.003 0.967
logTBARS 0.076 0.070 0.079 0.283
BMI 0.008 0.015 0.045 0.603
Verbal Memory Euthymic 0.345 0.145 0.199 0.019
Maniac 1.071 0.177 0.543 <0.0001
Current age 0.015 0.005 0.224 0.002
Premorbid IQ 0.018 0.005 0.279 <0.0001
BDNF 0.013 0.005 0.185 0.005
logIL6 0.053 0.110 0.037 0.628
logTNF 0.005 0.020 0.015 0.813
logTBARS 0.088 0.063 0.091 0.166
BMI 0.040 0.014 0.219 0.005
Visual Memory Euthymic 0.325 0.172 0.163 0.061
Maniac 0.742 0.209 0.327 0.001
Current age 0.026 0.006 0.331 <0.0001
Premorbid IQ 0.032 0.006 0.432 <0.0001
BDNF <0.0001 0.005 0.006 0.931
logIL6 0.150 0.130 0.090 0.252
logTNF 0.046 0.024 0.125 0.054
logTBARS 0.113 0.075 0.101 0.134
BMI 0.010 0.016 0.046 0.556
Abbreviations: IQ: intelligence quotient; BMI: body mass index.
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0.066, p = 0.011) was the only clinical variable that was associated
with worse performance on the attention domain, together with
current age (β=0.025, p = 0.001) and premorbid IQ (β = 0.014,
p = 0.015), and explained a 32% of variance (F = 2.7; df = 12, 70;
p = 0.004). The rest of clinical variables were not associated with
any of the other domains.
Verbal memory was associated with BDNF levels (β = 0.023,
p = 0.001), BMI (β=0.05, p = 0.017), together with being manic(β=0.864, p < 0.0001), current age (β=0.018, p = 0.023) and pre-
morbid IQ (β = 0.022, p = 0.001), and explained a 54% of variance
(F = 7; df = 12, 70; p < 0.0001).
4. Discussion
The most remarkable finding of this study was the significant
association of neurotrophins with illness phases and their
significant impact on cognitive dysfunction in bipolar individuals,
Fig. 2. Scatter plots displaying predicted executive functioning (a) and verbal memory (b) by BDNF levels clustered by euthymic and manic bipolar individuals and healthy
controls.
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This represents valuable information as few studies have explored
the role of neurobiological factors on cognitive symptoms in BD,
and results had been contradictory.
Linking neurobiological factors and cognition, our results are
partially consistent with the few previous studies that focus on
BNDF and cognitive outcome in BD, specifically in executive
functioning [45] and verbal memory [46,47]. In the same line, TNF-
α, was found to be negatively correlated with accuracy on the
delayed memory component on the Rey Auditory Verbal Learning
Test (RAVLT) in euthymic type I individuals [48]. Remarkably, the
presence of verbal memory impairment across mood phases may
indicate that these deficits are trait markers of bipolar illness [49].
Furthermore, current evidence indicates that the BD phenotype
is heterogeneous and there may be different illness trajectories
that could at least in part be explained by distinct underlying
pathophysiology [50,51]. The current study provides evidence that
other conditions such as obesity can play a role in defining verbal
memory as a trait marker, as has been observed in previous studies
[52–54]. In a recent study from our group, the interaction of bipolar
disorder and obesity was found to impact cognitive dysfunction at
a single point in time and long-term [14].
Strikingly, the relation between BDNF and verbal memory
found in our study has not been replicated in healthy population in
a recent study [55]. There are also previous data showing a positive
[56], a negative [57] or no correlation [58] between serum BDNF
and memory functions in healthy subjects. All these conflicting
results could be explained by the fact that the relationship
between cognition and BDNF may be affected by many other
factors such as mood state, sociodemographic and lifestyle factors
(for example: physical exercise, BMI and others) [55]. In the same
line, BDNF Val66Met genotype has been described as a potential
risk factor for obesity and insulin resistance measures in patients
with BD who are also receiving antipsychotic medication [59].
Regarding the association between clinical variables and
neurobiological factors, duration of illness was the only clinical
variable related with an inflammatory marker (IL-6) in the current
study. In the same line, another study found that IL-6 levels
showed significant differences between early and late stages of BD
[60]. Consistent with our results, in a recent meta-analysis [21],duration of illness in euthymia was not associated with BDNF
levels, suggesting that it may not be a useful marker of illness stage
but it could be a marker of illness activity instead. Furthermore, it
has been reported that BDNF levels did not differ between bipolar
patients, unaffected first-degree relatives and healthy controls.
Thus, BDNF levels may not reflect high genetic risk for BD, acting as
state marker rather than trait marker for the disease [61]. The
correlation of BDNF levels with mood psychometric scales and
mood phases may corroborate this hypothesis.
In terms of the association between psychopharmacological
treatment and neurobiological factors, in our study lithium
variables were not significantly associated with BDNF levels which
may indicate that lithium did not influence the relationship
between neurotrophins and cognition. In this paper the impact of
psychopharmacological treatment on the association between
neurobiological factors and cognitive dysfunction was not directly
assessed because it was not methodologically designed for this
purpose. Focusing on lithium, it has been reported in the current
literature that excellent lithium responders (ELR) had higher
plasma BDNF levels and performed better on all neuropsychologi-
cal tests than the remaining lithium patients [62] but worse than
healthy controls in the long-term [63]. Treatment with mood
stabilizers (i.e. lithium) was associated with lower levels of DNA
methylation of BDNF promoter [64]. Further analyses of neurobio-
logical factors by selecting individuals taking lithium are
warranted to understand the effects of lithium on cognition.
In our study, neither inflammatory nor oxidative stress markers
were associated with cognitive performance, which differ from
previous studies [10,48,65]. Of note, many other difficult-to-control
factors related with mood symptoms which may result in
inflammation and oxidative stress, were not assessed such as:
undiagnosed inflammatory medical comorbidities, history of early
childhood adversity [66], dysfunctional gut-microbiota, dietary
patterns, and low-grade idiopathic systemic inflammation [67–72].
The reported discrepancies could arguably be attributed to
some methodological limitations of the current study that warrant
acknowledgement: the variety of techniques to measure neurobi-
ological factors, demographics and clinical characteristics of the
sample, such as age and gender-related brain characteristics [73],
BD subtype [74] and medication history [75]. Although the sample
Table 4
Multiple regression models of the association between neurobiological factors and cognition in bipolar disorder individuals (euthymic and manic). The values correspond to
all factors included in the models. Please note that only Verbal Memory model was the only that neurobiological factors were significant.
Cognitive Domain Predictor β Standard error β Standardized β p
Executive Functioning Maniac 0.333 0.148 0.226 0.028
Current age 0.032 0.006 0.565 <0.0001
Premorbid IQ 0.037 0.005 0.608 <0.0001
BDNF 0.003 0.005 0.047 0.555
logIL6 0.085 0.119 0.069 0.480
logTNF 0.011 0.020 0.044 0.584
logTBARS 0.080 0.060 0.107 0.184
BMI 0.016 0.017 0.100 0.334
Age at onset 0.004 0.006 0.055 0.552
Number of manic episodes 0.042 0.022 0.182 0.063
Number of depressive episodes 0.024 0.027 0.086 0.367
Inhibition Maniac 0.205 0.205 0.125 0.321
Current age 0.038 0.008 0.594 <0.0001
Premorbid IQ 0.023 0.007 0.341 0.001
BDNF 0.010 0.007 0.130 0.187
logIL6 0.023 0.165 0.017 0.890
logTNF 0.025 0.028 0.087 0.382
logTBARS 0.111 0.083 0.133 0.184
BMI 0.019 0.023 0.107 0.405
Age at onset 0.015 0.009 0.201 0.085
Number of manic episodes 0.052 0.031 0.200 0.101
Number of depressive episodes 0.065 0.037 0.207 0.084
Attention Maniac 0.179 0.169 0.138 0.294
Current age 0.016 0.007 0.322 0.019
Premorbid IQ 0.014 0.006 0.264 0.016
BDNF 0.003 0.006 0.055 0.590
logIL6 0.040 0.136 0.038 0.769
logTNF 0.035 0.023 0.155 0.139
logTBARS 0.091 0.068 0.140 0.184
BMI 0.011 0.019 0.08 0.550
Age at onset 0.009 0.007 0.150 0.217
Number of manic episodes 0.065 0.026 0.323 0.013
Number of depressive episodes 0.020 0.031 0.08 0.522
Processing speed Maniac 0.323 0.221 0.178 0.148
Current age 0.048 0.009 0.689 <0.0001
Premorbid IQ 0.022 0.007 0.297 0.004
BDNF 0.005 0.008 0.057 0.552
logIL6 0.086 0.178 0.057 0.630
logTNF 0.009 0.030 0.028 0.770
logTBARS 0.050 0.089 0.054 0.579
BMI 0.018 0.025 0.088 0.481
Age at onset 0.010 0.009 0.117 0.299
Number of manic episodes 0.006 0.033 0.020 0.865
Number of depressive episodes 0.011 0.040 0.032 0.781
Verbal Memory Maniac 0.863 0.181 0.509 <0.0001
Current age 0.018 0.007 0.283 0.012
Premorbid IQ 0.022 0.006 0.309 0.001
BDNF 0.023 0.007 0.287 0.001
logIL6 0.084 0.146 0.060 0.568
logTNF 0.028 0.025 0.096 0.258
logTBARS 0.115 0.073 0.134 0.120
BMI 0.050 0.020 0.267 0.017
Age at onset 0.0000499 0.008 0.001 0.995
Number of manic episodes 0.017 0.027 0.065 0.533
Number of depressive episodes 0.007 0.033 0.022 0.830
Visual Memory Maniac 0.455 0.217 0.234 0.040
Current age 0.031 0.009 0.417 0.001
Premorbid IQ 0.036 0.007 0.444 <0.0001
BDNF 0.005 0.008 0.050 0.571
logIL6 0.114 0.175 0.071 0.515
logTNF 0.054 0.030 0.159 0.076
logTBARS 0.123 0.088 0.125 0.165
BMI 0.012 0.024 0.057 0.622
Age at onset 0.001 0.009 0.012 0.911
Number of manic episodes 0.024 0.033 0.079 0.467
Number of depressive episodes 0.046 0.040 0.124 0.245
Abbreviations: IQ: intelligence quotient; BMI: body mass index.
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E. Mora et al. / European Psychiatry 60 (2019) 97–107 105size of the present study is acceptable given the type of population,
the study should be seen as exploratory given the number of
statistical analyses conducted. In any case, these analyses served to
cover different aspects of the intricate variables involved in
cognitive performance of bipolar patients. In our sample euthymic
bipolar disorder individuals might represent mid-late stage of the
illness with low rates of recurrence which might not be
representative of the majority of bipolar patients, being biased
to patients with better outcomes [76]. But including manic
patients groups in the sample has allowed us to demonstrate
the cognitive consequences of neurotrophins in different mood
phases. Moreover, our sample was balanced in terms of gender and
there were no statistical differences between groups according to
BD type I and type II in terms of neurobiological factors levels. The
cross-sectional nature of the study and the methodological
limitations described above preclude the establishment of more
conclusive evidence about the neuroprogression or neurodeve-
lopmental nature of the illness or about the causality and direction
of the associations. But the correlation findings shed light on this
intriguing field. Some authors state that there may be a subgroup
of patients not exceeding 25–40% that could show phenomena of
cycle acceleration [77]. Moreover, there is growing evidence that
about one third of euthymic BD patients have more severe
cognitive deficits than usually reported in the literature, while a
similar proportion are indistinguishable from healthy controls in
terms of cognitive functioning [78]. Clinical evidence supporting
the concept of neuroprogression in BD is scarce and limited [79],
but the longitudinal studies that have been published to date are
too small and too short-term to prove that there is no progression
[80]. This controversy is currently still under debate [7]. Future
investigation using larger samples, drug-naïve patients, longitudi-
nal designs incorporating repeated measures of these markers
[81], selecting homogenous treatment response like excellent
lithium responders and assessing the impact of childhood trauma
[66] and lifestyle factors (for example: physical exercise and BMI)
[55] are needed to reveal the specific connections between BD,
neurobiological factors and neurocognitive performance. A careful
attention to attrition in those cohorts will be critical.
4.1. Conclusion
In conclusion, our findings support the hypothesis that neuro-
trophic mechanisms correlate with clinical variables and cognitive
functioning, specifically in executive functioning and verbal
memory. Other variables such as mood state and obesity may
underlie the link between neurotrophins and cognition. Additional
work is needed to understand how pro-inflammatory and oxidative
damage processes affect brain function and induce cognitive
impairment [10]. Monitoring neurobiological factors levels at the
time of assessment in clinical psychiatry could help to tailor specific
and individualized treatment interventions not only to treat mood
symptoms but also to revert biological changes associated with the
illness [16] such as cognitive and functional decline.
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